


RAW SEQUENCE LISTING **ERROR REPORT**



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following CRF diskette:

Application Serial Number: 09/285,531
Art Unit / Team No. : OIPK
Date Processed by STIC: 4/27/99

THE ATTACHED PRINTOUT EXPLAINS THE ERRORS DETECTED.

PLEASE BE SURE TO FORWARD THIS INFORMATION TO THE APPLICANTS BY EITHER:

1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANTS ALONG WITH A NOTICE TO COMPLY or,

2) CALLING APPLICANTS AND FAXING THEM A COPY OF THE PRINTOUT WITH A NOTICE TO COMPLY

THIS WILL INSURE THAT THE NEXT SUBMISSION RECEIVED FROM THEM WILL BE ERROR FREE.

IF YOU HAVE ANY FURTHER QUESTIONS, PLEASE CALL:

ARTI SHAH 703-308-4212

Raw Sequence Listing Error Summary

ERROR DETECTED SUGGESTED CORRECTION

SERIAL NUMBER: 09/285,531

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1 **Wrapped Nucleics** The number/text at the end of each line "wrapped" down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".
- 2 **Wrapped Aminos** The amino acid number/text at the end of each line "wrapped" down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".
- 3 **Incorrect Line Length** The rules require that a line not exceed 72 characters in length. This includes spaces.
All text must be visible on page.
- 4 **Misaligned Amino Acid
Numbering** The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs
between the numbering. It is recommended to delete any tabs and uses spacing between the numbers.
- 5 **Non-ASCII** This file was not saved in ASCII (DOS) text, as required by the Sequence Rules.
Please ensure your subsequent submission is saved in ASCII text so that it can be processed.
- 6 **Variable Length** Sequence(s) contain n's or Xaa's which represented more than one residue.
As per the rules, each n or Xaa can only represent a single residue.
Please present the maximum number of each residue having variable length and
indicate in the (ix) features section that some may be missing.
- 7 **Wrong Designation** Sequence(s) contain amino acid or nucleic acid designators which are not standard
representations as per the Sequence Rules (Please refer to paragraph 1.822)
- 8 **Skipped Sequences
(OLD RULES)** Sequence(s) missing. If intentional, please use the following format for each skipped sequence:
(2) INFORMATION FOR SEQ ID NO:X:
(i) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTICS")
(x1) SEQUENCE DESCRIPTION:SEQ ID NO:X:
This sequence is intentionally skipped

Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).
- 9 **Skipped Sequences
(NEW RULES)** Sequence(s) missing. If intentional, please use the following format for each skipped sequence.
<210> sequence id number
<400> sequence id number
000
- 10 **Use of n's or Xaa's
(NEW RULES)** Use of n's and/or Xaa's have been detected in the Sequence Listing.
Use of <220> to <223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
- 11 **Use of <213>Organism
(NEW RULES)** Sequence(s) are missing this mandatory field or its response.
- 12 ✓ **Use of <220>Feature
(NEW RULES)** Sequence(s) 1, 2 are missing the <220>Feature and associated headings.
Use of <220> to <223> is MANDATORY if <213>ORGANISM is "Artificial" or "Unknown"
Please explain source of genetic material in <220> to <223> section.
(See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32)
(Sec. 1.823 of new Sequence Rules)
- 13 **PatentIn ver. 2.0 "bug"** Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted
file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing).
Instead, please use "File Manager" or any other means to copy file to floppy disk.

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. §§ 1.821-1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990, and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. § 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. § 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. §§ 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing".
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. § 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. § 1.821(e).
- ☐ 7. Other:

Applicant must provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. § 1.821(e) or § 1.821(f) or § 1.821(g) or § 1.825(b) or § 1.825(d).

For questions regarding compliance with these requirements, please contact one of the following:

For rules interpretation, call (703) 308-4216.
For CRF submission help, call (703) 308-4212.
For PatentIn software help, call (703) 557-0400.

Please return a copy of this notice with your response.

PAGE: 1

RAW SEQUENCE LISTING

PATENT APPLICATION US/09/285,531

 DATE: 04/27/1999
 TIME: 10:25:59

Input Set: I285531.RAW

This Raw Listing contains the General Information
 Section and up to first 5 pages.

Does Not Comply
 Corrected Diskette Needed

1 <110> APPLICANT: Chernajovsky, Yuti
 2 Neve, Richard
 3 Feldmann, Marc
 4 <120> TITLE OF INVENTION: Small Molecular Weight TNF Receptor Multimeric Molecule
 5 <130> FILE REFERENCE: KIR95-01A
 6 <140> CURRENT APPLICATION NUMBER: US/09/285,531
 7 <141> CURRENT FILING DATE: 1999-04-02
 8 <150> EARLIER APPLICATION NUMBER: 08/437,533
 9 <151> EARLIER FILING DATE: 1995-05-09
 10 <160> NUMBER OF SEQ ID NOS: 4
 11 <170> SOFTWARE: FastSEQ for Windows Version 3.0
 12 <210> SEQ ID NO 1
 13 <211> LENGTH: 1506
 14 <212> TYPE: DNA
 15 <213> ORGANISM: Unknown
 16 <220> FEATURE:
 17 <221> NAME/KEY: CDS
 18 <222> LOCATION: (1)...(1506)
 19 <400> SEQUENCE: 1

20 atg gcg ccc gtc gcc gtc tgg gcc gcg ctg gcc gtc gga ctg gag ctc 48
 21 Met Ala Pro Val Ala Val Trp Ala Ala Leu Ala Val Gly Leu Glu Leu
 22 1 5 10 15
 23 tgg gct gcg gcg cac gcc ttg ccc gcc cag gtg gca ttt aca ccc tac 96
 24 Trp Ala Ala Ala His Ala Leu Pro Ala Gln Val Ala Phe Thr Pro Tyr
 25 20 25 30
 26 gcc ccg gag ccc ggg agc aca tgc cgg ctc aga gaa tac tat gac cag 144
 27 Ala Pro Glu Pro Gly Ser Thr Cys Arg Leu Arg Glu Tyr Tyr Asp Gln
 28 35 40 45
 29 aca gct cag atg tgc tgc agc aaa tgc tgc ccg ggc caa cat gca aaa 192
 30 Thr Ala Gln Met Cys Cys Ser Lys Cys Ser Pro Gly Gln His Ala Lys
 31 50 55 60
 32 gtc ttc tgt acc aag acc tgc gac acc gtg tgt gac tcc tgt gag gac 240
 33 Val Phe Cys Thr Lys Thr Ser Asp Thr Val Cys Asp Ser Cys Glu Asp
 34 65 70 75 80
 35 agc aca tac acc cag ctc tgg aac tgg gtt ccc gag tgc ttg agc tgt 288
 36 Ser Thr Tyr Thr Gln Leu Trp Asn Trp Val Pro Glu Cys Leu Ser Cys
 37 85 90 95
 38 ggc tcc cgc tgt agc tct gac cag gtg gaa act caa gcc tgc act cgg 336
 39 Gly Ser Arg Cys Ser Ser Asp Gln Val Glu Thr Gln Ala Cys Thr Arg
 40 100 105 110
 41 gaa cag aac cgc atc tgc acc tgc agg ccc gcc tgg tac tgc gcg ctg 384
 42 Glu Gln Asn Arg Ile Cys Thr Cys Arg Pro Gly Trp Tyr Cys Ala Leu
 43 115 120 125
 44 agc aag cag gag ggg tgc cgg ctg tgc gcg ccg ctg cgc aag tgc cgc 432

pp 1,3
see item 12 on Ena summary sheet

PAGE: 2

RAW SEQUENCE LISTING
PATENT APPLICATION US/09/285,531

DATE: 04/27/1999
TIME: 10:25:59

Input Set: I285531.RAW

45	Ser	Lys	Gln	Glu	Gly	Cys	Arg	Leu	Cys	Ala	Pro	Leu	Arg	Lys	Cys	Arg	
46		130					135					140					
47	ccg	ggc	ttc	ggc	gtg	gcc	aga	cca	gga	act	gaa	aca	tca	gac	gtg	gtg	480
48	Pro	Gly	Phe	Gly	Val	Ala	Arg	Pro	Gly	Thr	Glu	Thr	Ser	Asp	Val	Val	
49	145					150				155					160		
50	tgc	aag	ccc	tgt	gcc	ccg	ggg	acg	ttc	tcc	aac	acg	act	tca	tcc	acg	528
51	Cys	Lys	Pro	Cys	Ala	Pro	Gly	Thr	Phe	Ser	Asn	Thr	Thr	Ser	Ser	Thr	
52				165					170				175				
53	gat	att	tgc	agg	ccc	cac	cag	atc	tgt	aac	gtg	gtg	gcc	atc	cct	ggg	576
54	Asp	Ile	Cys	Arg	Pro	His	Gln	Ile	Cys	Asn	Val	Val	Ala	Ile	Pro	Gly	
55			180					185					190				
56	aat	gca	agc	atg	gat	gca	gtc	tgc	acg	tcc	acg	tcc	ccc	acc	cgg	agt	624
57	Asn	Ala	Ser	Met	Asp	Ala	Val	Cys	Thr	Ser	Thr	Ser	Pro	Thr	Arg	Ser	
58			195				200						205				
59	atg	gcc	cca	ggg	gca	gta	cac	tta	ccc	cag	cca	gtg	tcc	aca	cga	tcc	672
60	Met	Ala	Pro	Gly	Ala	Val	His	Leu	Pro	Gln	Pro	Val	Ser	Thr	Arg	Ser	
61		210				215						220					
62	caa	cac	acg	cag	cca	act	cca	gaa	ccc	agc	act	gct	cca	agc	acc	tcc	720
63	Gln	His	Thr	Gln	Pro	Thr	Pro	Glu	Pro	Ser	Thr	Ala	Pro	Ser	Thr	Ser	
64	225				230					235					240		
65	ttc	ctg	ctc	cca	atg	ggc	ccc	agc	ccc	cca	gct	aga	ggg	ggg	ggc	ggg	768
66	Phe	Leu	Leu	Pro	Met	Gly	Pro	Ser	Pro	Pro	Ala	Arg	Gly	Gly	Gly	Gly	
67			245					250					255				
68	tgc	ggg	ggc	ggc	ggc	tgc	ggc	ggg	ggg	ggc	tgc	gat	ccc	gcc	cag	gtg	816
69	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Asp	Pro	Ala	Gln	Val	
70			260					265					270				
71	gca	ttt	aca	ccc	tac	gcc	ccg	gag	ccc	ggg	agc	aca	tgc	cgg	ctc	aga	864
72	Ala	Phe	Thr	Pro	Tyr	Ala	Pro	Glu	Pro	Gly	Ser	Thr	Cys	Arg	Leu	Arg	
73			275					280					285				
74	gaa	tac	tat	gac	cag	aca	gct	cag	atg	tgc	tgc	agc	aaa	tgc	tgc	ccg	912
75	Glu	Tyr	Tyr	Asp	Gln	Thr	Ala	Gln	Met	Cys	Cys	Ser	Lys	Cys	Ser	Pro	
76		290				295						300					
77	ggc	caa	cat	gca	aaa	gtc	ttc	tgt	acc	aag	acc	tgc	gac	acc	gtg	tgt	960
78	Gly	Gln	His	Ala	Lys	Val	Phe	Cys	Thr	Lys	Thr	Ser	Asp	Thr	Val	Cys	
79	305				310					315					320		
80	gac	tcc	tgt	gag	gac	agc	aca	tac	acc	cag	ctc	tgg	aac	tgg	gtt	ccc	1008
81	Asp	Ser	Cys	Glu	Asp	Ser	Thr	Tyr	Thr	Gln	Leu	Trp	Asn	Trp	Val	Pro	
82			325					330					335				
83	gag	tgc	ttg	agc	tgt	ggc	tcc	cgc	tgt	agc	tct	gac	cag	gtg	gaa	act	1056
84	Glu	Cys	Leu	Ser	Cys	Gly	Ser	Arg	Cys	Ser	Ser	Asp	Gln	Val	Glu	Thr	
85			340					345					350				
86	caa	gcc	tgc	act	cgg	gaa	cag	aac	cgc	atc	tgc	acc	tgc	agg	ccc	ggc	1104
87	Gln	Ala	Cys	Thr	Arg	Glu	Gln	Asn	Arg	Ile	Cys	Thr	Cys	Arg	Pro	Gly	
88			355					360					365				
89	tgg	tac	tgc	gcg	ctg	agc	aag	cag	gag	ggg	tgc	cgg	ctg	tgc	gcg	ccg	1152
90	Trp	Tyr	Cys	Ala	Leu	Ser	Lys	Gln	Glu	Gly	Cys	Arg	Leu	Cys	Ala	Pro	
91		370				375						380					
92	ctg	cgc	aag	tgc	cgc	ccg	ggc	ttc	ggc	gtg	gcc	aga	cca	gga	act	gaa	1200
93	Leu	Arg	Lys	Cys	Arg	Pro	Gly	Phe	Gly	Val	Ala	Arg	Pro	Gly	Thr	Glu	
94	385					390					395				400		

PAGE: 3

RAW SEQUENCE LISTING
PATENT APPLICATION US/09/285,531

DATE: 04/27/1999
TIME: 10:25:59

Input Set: I285531.RAW

95 aca tca gac gtg gtg tgc aag ccc tgt gcc ccg ggg acg ttc tcc aac 1248
96 Thr Ser Asp Val Val Cys Lys Pro Cys Ala Pro Gly Thr Phe Ser Asn
97 405 410 415
98 acg act tca tcc acg gat att tgc agg ccc cac cag atc tgt aac gtg 1296
99 Thr Thr Ser Ser Thr Asp Ile Cys Arg Pro His Gln Ile Cys Asn Val
100 420 425 430
101 gtg gcc atc cct ggg aat gca agc atg gat gca gtc tgc acg tcc acg 1344
102 Val Ala Ile Pro Gly Asn Ala Ser Met Asp Ala Val Cys Thr Ser Thr
103 435 440 445
104 tcc ccc acc cgg agt atg gcc cca ggg gca gta cac tta ccc cag cca 1392
105 Ser Pro Thr Arg Ser Met Ala Pro Gly Ala Val His Leu Pro Gln Pro
106 450 455 460
107 gtg tcc aca cga tcc caa cac acg cag cca act cca gaa ccc agc act 1440
108 Val Ser Thr Arg Ser Gln His Thr Gln Pro Thr Pro Glu Pro Ser Thr
109 465 470 475 480
110 gct cca agc acc tcc ttc ctg ctc cca atg ggc ccc agc ccc cca gct 1488
111 Ala Pro Ser Thr Ser Phe Leu Leu Pro Met Gly Pro Ser Pro Pro Ala
112 485 490 495
113 gaa ggg agc act ggc tag 1506
W--> 114 Glu Gly Ser Thr Gly
115 500
116 <210> SEQ ID NO 2
117 <211> LENGTH: 501
118 <212> TYPE: PRT
119 <213> ORGANISM: Unknown *Item 12*
120 <400> SEQUENCE: 2
121 Met Ala Pro Val Ala Val Trp Ala Ala Leu Ala Val Gly Leu Glu Leu
122 1 5 10 15
123 Trp Ala Ala Ala His Ala Leu Pro Ala Gln Val Ala Phe Thr Pro Tyr
124 20 25 30
125 Ala Pro Glu Pro Gly Ser Thr Cys Arg Leu Arg Glu Tyr Tyr Asp Gln
126 35 40 45
127 Thr Ala Gln Met Cys Cys Ser Lys Cys Ser Pro Gly Gln His Ala Lys
128 50 55 60
129 Val Phe Cys Thr Lys Thr Ser Asp Thr Val Cys Asp Ser Cys Glu Asp
130 65 70 75 80
131 Ser Thr Tyr Thr Gln Leu Trp Asn Trp Val Pro Glu Cys Leu Ser Cys
132 85 90 95
133 Gly Ser Arg Cys Ser Ser Asp Gln Val Glu Thr Gln Ala Cys Thr Arg
134 100 105 110
135 Glu Gln Asn Arg Ile Cys Thr Cys Arg Pro Gly Trp Tyr Cys Ala Leu
136 115 120 125
137 Ser Lys Gln Glu Gly Cys Arg Leu Cys Ala Pro Leu Arg Lys Cys Arg
138 130 135 140
139 Pro Gly Phe Gly Val Ala Arg Pro Gly Thr Glu Thr Ser Asp Val Val
140 145 150 155 160
141 Cys Lys Pro Cys Ala Pro Gly Thr Phe Ser Asn Thr Thr Ser Ser Thr
142 165 170 175
143 Asp Ile Cys Arg Pro His Gln Ile Cys Asn Val Val Ala Ile Pro Gly
144 180 185 190

PAGE: 4

RAW SEQUENCE LISTING
PATENT APPLICATION US/09/285,531

DATE: 04/27/1999

TIME: 10:25:59

Input Set: I285531.RAW

```

145      Asn Ala Ser Met Asp Ala Val Cys Thr Ser Thr Ser Pro Thr Arg Ser
146              195                      200                      205
147      Met Ala Pro Gly Ala Val His Leu Pro Gln Pro Val Ser Thr Arg Ser
148              210                      215                      220
149      Gln His Thr Gln Pro Thr Pro Glu Pro Ser Thr Ala Pro Ser Thr Ser
150      225                      230                      235                      240
151      Phe Leu Leu Pro Met Gly Pro Ser Pro Pro Ala Arg Gly Gly Gly Gly
152              245                      250                      255
153      Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Pro Ala Gln Val
154              260                      265                      270
155      Ala Phe Thr Pro Tyr Ala Pro Glu Pro Gly Ser Thr Cys Arg Leu Arg
156              275                      280                      285
157      Glu Tyr Tyr Asp Gln Thr Ala Gln Met Cys Cys Ser Lys Cys Ser Pro
158              290                      295                      300
159      Gly Gln His Ala Lys Val Phe Cys Thr Lys Thr Ser Asp Thr Val Cys
160      305                      310                      315                      320
161      Asp Ser Cys Glu Asp Ser Thr Tyr Thr Gln Leu Trp Asn Trp Val Pro
162              325                      330                      335
163      Glu Cys Leu Ser Cys Gly Ser Arg Cys Ser Ser Asp Gln Val Glu Thr
164              340                      345                      350
165      Gln Ala Cys Thr Arg Glu Gln Asn Arg Ile Cys Thr Cys Arg Pro Gly
166              355                      360                      365
167      Trp Tyr Cys Ala Leu Ser Lys Gln Glu Gly Cys Arg Leu Cys Ala Pro
168              370                      375                      380
169      Leu Arg Lys Cys Arg Pro Gly Phe Gly Val Ala Arg Pro Gly Thr Glu
170      385                      390                      395                      400
171      Thr Ser Asp Val Val Cys Lys Pro Cys Ala Pro Gly Thr Phe Ser Asn
172              405                      410                      415
173      Thr Thr Ser Ser Thr Asp Ile Cys Arg Pro His Gln Ile Cys Asn Val
174              420                      425                      430
175      Val Ala Ile Pro Gly Asn Ala Ser Met Asp Ala Val Cys Thr Ser Thr
176              435                      440                      445
177      Ser Pro Thr Arg Ser Met Ala Pro Gly Ala Val His Leu Pro Gln Pro
178              450                      455                      460
179      Val Ser Thr Arg Ser Gln His Thr Gln Pro Thr Pro Glu Pro Ser Thr
180      465                      470                      475                      480
181      Ala Pro Ser Thr Ser Phe Leu Leu Pro Met Gly Pro Ser Pro Pro Ala
182              485                      490                      495
183      Glu Gly Ser Thr Gly
184              500

```

<210> SEQ ID NO 3

<211> LENGTH: 30

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: deoxyoligonucleotide primer

<400> SEQUENCE: 3

tcggatcccg cccaggtggc atttacaccc

<210> SEQ ID NO 4

<211> LENGTH: 20

PAGE: 5

RAW SEQUENCE LISTING
PATENT APPLICATION US/09/285,531DATE: 04/27/1999
TIME: 10:25:59

Input Set: I285531.RAW

195 <212> TYPE: DNA
196 <213> ORGANISM: Artificial Sequence
197 <220> FEATURE:
198 <223> OTHER INFORMATION: deoxyoligonucleotide primer
199 <400> SEQUENCE: 4
200 cggaattcta gaaggtaccc

20

PAGE: 6

VERIFICATION SUMMARY
PATENT APPLICATION US/09/285,531

DATE: 04/27/1999
TIME: 10:25:59

Input Set: I285531.RAW

Line ? Error/Warning

Original Text

114 W Line data has been corrected

Glu Gly Ser Thr Gly *

PAGE: 7

CORRECTION SUMMARY
PATENT APPLICATION US/09/285,531

DATE: 04/27/1999
TIME: 10:25:59

Input Set: I285531.RAW

Line Original Text

Corrected Data

114 Glu Gly Ser Thr Gly *

Glu Gly Ser Thr Gly